Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background

Ann N Y Acad Sci. 2000;920:171-8. doi: 10.1111/j.1749-6632.2000.tb06919.x.

Abstract

Several lines of evidence implicate apolipoprotein E (apoE) and its receptor--the low density lipoprotein receptor related protein (LRP)--in Alzheimer's disease (AD) pathogenesis, including increased amyloid deposition in human AD brains of people containing the apoE epsilon 4 allele, presence of apoE and LRP in amyloid plaques, and in vitro uptake of amyloid precursor protein (APP) and amyloid beta protein (A beta) by LRP. Studies of crosses of apoE knockout mice with APP transgenic mice support a complex interaction between apoE and A beta deposition. In the Tg2576 mice expressing human APPK670N-M671L, apoE determines the amount, morphology, vascular pattern, and neuropil response to A beta deposits. In the PDAPP mice expressing human APPV717F, apoE also affects the anatomical localization of cerebral A beta deposits. Thus, APP transgenic mice can serve as models to investigate genetic influences on the amount and timing of cerebral amyloidosis, the morphology of amyloid plaques, and the vulnerability of specific neuroanatomical regions to A beta deposition.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Alzheimer Disease / genetics
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / analysis
  • Amyloid beta-Peptides / genetics*
  • Amyloid beta-Protein Precursor / genetics*
  • Animals
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / genetics*
  • Brain / pathology
  • Humans
  • Mice
  • Mice, Knockout
  • Mice, Transgenic

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Apolipoproteins E